Combination therapy before surgery improves outcomes for patients with HER2 positive breast cancer

Elucidation and pharmacological targeting of tumour checkpoint dependencies

Metastasis intiation mediated by thrombospondin 2

New technology can potentially overcome CAR T-cell limitations

AML17 Trial results: maximum dosage of daunorubicin in AML

BSH 2016: Expert discussion on front line care in CLL

BSH 2016: Expert discussion on idelalisib

Comparison of three different PD-L1 diagnostic tests shows a high degree of concordance

Next-generation sequencing in the lymphoid malignancies

Mutational clonality and intratumour heterogeneity as biomarkers for cancer immunotherapy

Retroviral replicating vectors for cancer-targeted gene therapy and immunotherapy

NY-ESO-1 immunotherapy for ovarian cancer